Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials

Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials

Abstract Isatuximab, an anti-CD38 monoclonal antibody, has been shown to induce apoptosis in multiple myeloma (MM) cells and is effective in both relapsed/refractory and newly diagnosed MM cases. This study aims to compare the safety profile of isatuximab by examining a broader range of adverse even...

Full description

Bibliographic Details
Main Authors: Muhammed Favas Karimbanathottathil, Beema T Yoosuf, M Mamatha, Dipika Bansal
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Scientific Reports
Subjects:
Isatuximab
Multiple myeloma
Safety
Adverse events
Disproportionality
Meta-analysis
Online Access:https://doi.org/10.1038/s41598-024-83014-1

Internet

https://doi.org/10.1038/s41598-024-83014-1

Similar Items